Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01796-6
Abstract: Cancer immunotherapy represents one of the most important innovations in modern medicine. Durvalumab is an anti-programmed cell death ligand 1 (PDL-1) agent which is currently under investigation in several studies in combination with the anti-cytotoxic… read more here.
Keywords: tremelimumab; solid tumors; durvalumab; plus tremelimumab ... See more keywords
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases
Sign Up to like & getrecommendations! Published in 2022 at "npj Breast Cancer"
DOI: 10.1038/s41523-022-00404-2
Abstract: Breast cancer brain metastases (BCBM) are a common and devastating complication of metastatic breast cancer with conventional systemic therapies demonstrating limited effectiveness. Consequently, radiotherapy (RT) ± surgery remains the cornerstone of BCBM management. Because preclinical and clinical… read more here.
Keywords: tremelimumab; cancer brain; breast cancer; trastuzumab ... See more keywords
Abstract CT113: Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-ct113
Abstract: Background : The anti-PD-L1 antibody durvalumab (D) has shown manageable safety and encouraging clinical activity in patients with advanced NSCLC. Combination of D with anti-CTLA-4 antibody tremelimumab (T) may amplify T-cell responses against tumors through… read more here.
Keywords: tremelimumab; non squamous; safety; advanced nsclc ... See more keywords
Abstract CT057: Safety and efficacy of durvalumab in combination with tremelimumab in patients with advanced gastric cancer with elevated tumor interferon-γ gene signature
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct057
Abstract: Background: Anti-PD-L1 and anti-CTLA-4 agents have demonstrated clinical activity in gastric and gastroesophageal junction cancer (GC/GEJC) tumors. However, response rates are low suggesting clinical benefit in only a subset of the population. This study prospectively… read more here.
Keywords: tremelimumab; ifn gene; cancer; signature ... See more keywords
Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Oncotarget"
DOI: 10.18632/oncotarget.26893
Abstract: Immunotherapy has shown modest activity in metastatic breast cancer (MBC). In this phase I dose escalation study, we assessed safety of tremelimumab, a humanized anti-CTLA4 monoclonal antibody, at starting dose 3 mg/kg, on the third… read more here.
Keywords: tremelimumab; metastatic breast; phase; breast cancer ... See more keywords